Cef menoxime hydrochloride is a third generation cephalosporin antibiotic.
Structurally, it possesses the (1-methyl-lH-tetrazol-5-yl)thiomethyl moiety in
the 3-position; like several other compounds containing this structural element
(moxalactam, cefoperazone, cefamandol), bleeding linked to vitamin K interaction
has been reported. Cefmenoxime has activity similar to cefotiuime, ceftizoxime
and moxalactam against E.coli, C. diversus, Klebsiella, P. Mirabilis, Salmonella,
Shigella, Neiseria spp., S. pyogenes, S. Pneumoniae, and g. influenzae. It is
relatively ineffective against Pseudomonas and Bacteroidea.
A third generation cephalosporin antibiotic with strong antimicrobial activities against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella subgenus Branhamella catarrhalis that were 3 major aerobic bacteria from sinusitis.
Cefmenoxime was synthesized by Takeda Pharmaceutical Co. in 1978. It contains aminothiazole and methoxyimino groups in the 7-acyl position and a methyltetrazole group at the 3 position of the cephem nucleus. Cefmenoxime has a wide activity spectrum against gram-positive and gram-negative bacteria, including anaerobes, except Staphylococcus aureus. Cefmenoxime is a member of the so-called third-generation cephalosporins, a recently introduced class of clinically important antibiotics.
